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Abstract: Insomnia, the most common sleep disturbance in later life, affects 20%–50% of 
older adults. Eszopiclone, a short-acting nonbenzodiazepine hypnotic agent developed for 
the treatment of insomnia, has been available in Europe since 1992 and in the US since 2005. 
Although not yet evaluated for transient insomnia in older adults, eszopiclone has been shown 
to be safe and efﬁ  cacious for short-term treatment (2 weeks) of chronic, primary insomnia in 
older adults (64–91 years). Clinical studies in younger adults (mean = 44 years) have shown 
eszopiclone can be used for 6–12 months without evidence of problems. Because the oldest 
participant in these longer-term trials was 69, it not known whether eszopiclone is effective 
for older adults [particularly the old old (75–84 years) and oldest old (85+)] when used over 
longer periods. This is unfortunate, because older individuals frequently suffer from chronic 
insomnia. Cognitive-behavioral therapy for insomnia, which effectively targets the behavioral 
factors that maintain chronic insomnia, represents an attractive treatment alternative or adjuvant 
to eszopiclone for older adults. To date, no studies have compared eszopiclone to other hypnotic 
medications or to nonpharmacological interventions, such as cognitive-behavioral therapy for 
insomnia, in older adults. All of the clinical trials reported herein were funded by Sepracor. 
This paper provides an overview of the literature on eszopiclone with special emphasis on 
its use for the treatment of late-life insomnia. Speciﬁ  c topics covered include pharmacology, 
pharmacodynamics, pharmacokinetics, clinical trial data, adverse events, drug interactions, 
tolerance/dependence, and economics/cost considerations for older adults.
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Introduction
Insomnia, deﬁ  ned as difﬁ  culty initiating and/or maintaining sleep or nonrestorative 
sleep (American Psychiatric Association 1994), is the most common sleep disturbance 
in later life. Prevalence estimates for individuals 65 and older range from 20%–50% 
(compared to 9%–15% for the general adult population), and women have been found 
to be 40%–60% more likely to suffer from insomnia compared to men (Foley et al 
1995; Ohayon 2002; Lichstein et al 2004; Roberts et al 2004). Sleep maintenance 
difﬁ  culties (or unwanted awakenings during the night) are frequently believed to be 
problematic for older individuals. However, recent epidemiological evidence from 
the National Sleep Foundation (NSF) (Foley et al 2004) indicates a wider range 
of difﬁ  culties with approximately one-ﬁ  fth of older adults (deﬁ  ned in this study as 
individuals aged 55 and over) suffering from difﬁ  culty falling asleep, one-third from 
waking during the night, one-fourth from waking too early with difﬁ  culty returning to 
sleep, and one-third from unrefreshing sleep. Unfortunately, insomnia in older adults 
is both underdiagnosed and undertreated. Although 50% of the older adults sampled 
by the NSF reported experiencing at least one symptom of insomnia several times a 
week, only 4% had been diagnosed with insomnia and only 3% were receiving treat-
ment (Foley et al 2004).
Insomnia is often more severe in the elderly. Older adults with insomnia awaken 
more frequently and spend a greater percentage of their nights awake than do younger Clinical Interventions in Aging 2007:2(3) 314
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people with insomnia (Lichstein et al 2004). Insomnia can 
be classiﬁ  ed as acute/transient (1 month or less), persistent 
(more than 4 weeks), or chronic (lasting 6 months or more). 
Unfortunately, older adults are particularly susceptible to 
developing chronic insomnia (McCrae et al 2003, 2005). 
Age-related increases in the occurrences of chronic medical 
conditions such as heart disease, arthritis, stroke, or lung 
disease contribute to older adults’ increased risk of chronic 
insomnia (Foley et al 2004). Chronic late-life insomnia is 
associated with a variety of negative consequences, includ-
ing decreased quality of life, disturbed mood (particularly, 
depression and anxiety), disturbed quality of social interac-
tions, increased risk of nursing home placement, dependence 
on sleep medication, and impaired cognitive functioning 
(Hart et al 1995; Reynolds et al 1999; Roth and Ancoli-
Israel 1999).
Agents typically used to treat late-life insomnia include 
benzodiazepines, sedating antidepressants, and newer non-
benzodiazepine hypnotics. The benzodiazepines, which have 
been the ‘gold standard’ for treating insomnia for the past 
20–30 years, are starting to be replaced by the nonbenzodiaz-
epine agents. Eszopiclone, a short-acting nonbenzodiazepine 
hypnotic agent developed for the treatment of insomnia, has 
been available in Europe since 1992. In the US, eszopiclone 
received approval from the food and drug administration 
(FDA) in 2004 and became available in 2005 under the 
brand name, Lunesta (Sepracor). Eszopiclone’s properties are 
similar to those of zolpidem (Ambien), another popular non-
benzodiazepine hypnotic. While both agents may promote 
sleep initiation, eszopiclone’s longer half-life (6 hours vs 2.6 
hours) may provide an advantage for sleep maintenance and 
early morning awakening.
In the US, eszopiclone has the distinction of being the ﬁ  rst 
hypnotic agent with a controlled substance designation that 
does not have restrictions on its length of use. This distinc-
tion is based on clinical studies demonstrating eszopiclone 
can be used for 6–12 months without evidence of problems 
(eg, tolerance/dependence). Unfortunately, these studies con-
tained primarily younger adults (mean age of approximately 
44 years). Because the maximum age of participants in these 
trials was 69, there have been no longer term studies in the 
old-old (75–84) or oldest-old (85+) age groups. Additionally, 
eszopiclone has not been evaluated for transient insomnia 
in older adults. There have been 2 clinical studies in older 
adults (64–85 years) with chronic primary insomnia (Erman 
et al 2004; Scharf et al 2005). Neither of these studies have 
examined eszopiclone use in older adults for longer than 2 
weeks. To date, no studies have compared eszopiclone to 
other hypnotic medications or to nonpharmacological inter-
ventions for insomnia in older adults.
Eszopiclone
Methods used to evaluate and select 
literature
Both the MEDLINE and ISI Web of Science databases were 
used to conduct the literature search using the following 
terms: eszopiclone, Lunesta, eszopiclone and behavioral 
sleep treatments, and eszopiclone and older adults. Abstracts 
and articles relating to the pharmacology, pharmacodynam-
ics, and pharmacokinetics of eszopiclone that were published 
between June 2002 and 2006 were retrieved. Clinical trials 
and letters to the editor were also reviewed. Additionally, the 
manufacturer (Sepracor, Inc) (Anon 2005a) was contacted for 
the most up-to-date information about the product. Abstracts 
from more recent conferences were also reviewed. Overall, 
69 articles and abstracts were reviewed.
Description of drug
Eszopiclone (Lunesta) was approved by the Food and Drug 
Administration on December 15, 2004. Eszopiclone is 
prescribed for the treatment of insomnia. Eszopiclone, the 
S-isomer of zopiclone, has been available in Europe since 
1992 (Anon 2005a). It is a nonbenzodiazepine hypnotic 
agent of the cyclopyrrone class (sedative hypnotic class 
of drugs). Eszopiclone has a single chiral center with an 
(S)-conﬁ  guration (Sepracor 2005) and is formulated as ﬁ  lm-
coated tablets to be used for oral administration in 1 mg, 2 mg, 
or 3 mg tablets (Sepracor 2005). Eszopiclone is classiﬁ  ed 
as a schedule IV drug under the Controlled Substances Act. 
Identiﬁ  cation as a schedule IV drug means that eszopiclone 
has accepted medical use for treatment within the United 
States, has a low potential for abuse in comparison to drugs 
in schedule III, and may lead to limited physical or psycho-
logical dependence relative to drugs in schedule III (Chapter 
13 of Title 21 of the United States Code, 1970).
Pharmacology/pharmacodynamics
The pharmacology, or mechanism of action, of eszopiclone 
is unknown. Eszopiclone’s effect is believed to result from 
the interaction of the drug with GABA-receptor complexes 
that are located close to, or are coupled with, benzodiazepine 
receptors (Anon 2005d). Once the eszopiclone binds to the 
GABA-receptor complex, there is an increase in chloride 
transmission that subsequently depresses the central nervous 
system, slowing brain activity, and resulting in sedation 
(Drover 2004). Additionally, eszopiclone binds mini-Clinical Interventions in Aging 2007:2(3) 315
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mally to plasma proteins. Consequently, the absorption and 
distribution of the drug is minimally affected by other drugs 
that may be competing for protein binding sites, resulting in 
a lowered probability for drug interactions with drugs that 
strongly bind to plasma proteins (Laustsen 2005).
The chemical structure of eszopiclone is unrelated to 
imidazopyridines, pyrazolopyrimidines, benzodiazepines, 
barbiturates, or other drugs with known hypnotic properties 
(Sepracor 2005).
Pharmacokinetics
The pharmacokinetics (ie, the impact of the body on the 
drug) of eszopiclone can be discussed in terms of absorption, 
metabolization, elimination, and considerations for special 
populations. In healthy subjects (adults and elderly), eszopi-
clone is rapidly absorbed, with peak concentrations occurring 
within one hour (Sepracor 2005). There is not a selective 
reuptake of Eszopiclone by red blood cells as indicated by 
a blood to plasma ratio of less than one (Sepracor 2005). 
Absorption of eszopiclone may be reduced if it is taken with 
or immediately after a high-fat/heavy meal (Sepracor 2005). 
The metabolization of eszopiclone occurs primarily in the 
liver through oxidation and demethylation (the removal of a 
methyl group; Brielmaier 2006). Eszopiclone has a half-life 
of approximately six hours (Sepracor 2005). Older adults 
(65+) have a slightly prolonged elimination (approximately 
nine hours). Therefore, the starting dose of eszopiclone for 
elderly patients should be decreased to 1 mg and should 
not exceed 2 mg (Sepracor 2005). The pharmacokinetics of 
eszopiclone in men and women and all races participating in 
Phase 1 studies of eszopiclone were similar (Sepracor 2005). 
Special dosage considerations for elderly patients are further 
discussed below.
Indications
Eszopiclone is indicated for the treatment of insomnia 
(Sepracor 2005). It is speciﬁ  cally indicated for patients 
who experience difﬁ  culty falling asleep as well as for those 
who have sleep maintenance difﬁ  culty (ie, difﬁ  culty staying 
asleep) (Anon 2005a).
Dosage considerations for older adults
Starting dosage recommendations for elderly patients who 
primarily complain of difﬁ  culty with sleep onset is 1 mg 
immediately before bedtime. This contrasts with the recom-
mended starting dose of 2 mg for adults. Since some of the 
important adverse effects of sedative/hypnotic drugs appear 
to be related to the dosage (eg, impaired motor or cognitive 
performance), it is important to monitor the dosage in elderly 
patients who may be more sensitive to sedative/hypnotic 
drugs. If the primary complaint of the elderly patient is dif-
ﬁ  culty maintaining sleep, the recommended dose is 2 mg 
immediately before bedtime. Studies have shown that the 
2 mg dose in elderly patients produces the most consistent 
improvements in sleep maintenance (Erman et al 2004; 
Scharf et al 2005).
Specialized dosage recommendations also exist for those 
patients diagnosed with severe hepatic impairment (severe 
liver disease). In that case, the recommended starting dosage 
of eszopiclone is 1 mg as systemic exposure will be doubled 
in these individuals.
Clinical trial research
Trials in older adults
There are no published trials examining the effect of eszopi-
clone on transient insomnia in older adults. To date, only two 
clinical trials (Erman and colleagues (2004) and Scharf and 
colleagues (2005)) (total n = 495) have been conducted to 
examine the safety and efﬁ  cacy of eszopiclone in the treat-
ment of primary and chronic insomnia in older adults (rang-
ing from 64–85 years). Each of these trials were short-term 
(over a 2-week period), and none compared eszopiclone to 
another hypnotic or to nonpharmacological interventions. 
Nonpharmacological interventions for insomnia include 
cognitive-behavioral therapy, relaxation therapy, or exercise. 
Much of the data is limited to abstracts, and all clinical trials 
were funded by Sepracor, the manufacturer of eszopiclone. 
A brief description of the methods employed by these trials 
and their key outcomes is provided below. See Table 1 for 
an even more concise summary of these trials.
Erman and colleagues (2004) conducted a randomized, 
double-blind, placebo-controlled study of 264 adults 65–85 
years old. All participants met DSM-IV diagnostic criteria for 
primary insomnia. One hundred thirty six older adults were 
given eszopiclone 2 mg, and 128 received a placebo. Poly-
somnography was used to assess latency to persistent sleep, 
sleep efﬁ  ciency, wake time after sleep onset, and number of 
awakenings. An interactive voice response system was used 
in the morning to assess sleep parameters and in the evening 
to assess daytime function and sleep latency (SL), wake time 
after sleep onset (WASO), number of awakenings (NWAK), 
total sleep time (TST), depth and quality of sleep, and morning 
sleepiness. Quality of life was assessed using the Insomnia 
Severity Index and SF-36 questionnaires. Eszopiclone signiﬁ  -
cantly reduced objective latency to persistent sleep (p   0.001) 
and WASO (p   0.05) compared with placebo. Objective Clinical Interventions in Aging 2007:2(3) 316
McCrae et al
awakenings (p = 0.16) were reduced and SE (p = 0.04) was 
also improved with eszopiclone compared to placebo. Patient 
reported measures of sleep, including SL (p   0.0001), and 
WASO (p = 0.002) were also signiﬁ  cantly reduced. The 
Insomnia Severity Index total score (p = 0.001) and the SF-
36 domains of overall functioning (p = 0.045) and vitality 
(p = 0.056) were improved in the eszopiclone 2 mg group.
Scharf and colleagues (2005) conducted a randomized, 
double-blind, placebo-controlled, multi-centered 2 week 
study on the efﬁ  cacy and safety of eszopiclone. Elderly 
patients (n = 231) with primary insomnia between the ages 
of 65 and 85 received 1 mg, 2 mg, or a placebo. An inter-
active voice response system was used to obtain SL, TST, 
WASO, NWAK, daytime functioning, and quality of life. 
Results indicate that the eszopiclone 2 mg group had signiﬁ  -
cantly improved SL (p = 0.0034), TST (p = 0.0003), WASO 
(p   0.05), and sense of physical well-being (p   .05) com-
pared with placebo. The 1 mg group exhibited signiﬁ  cantly 
decreased SL (p   0.012) compared with placebo, but was 
not signiﬁ  cant on any other efﬁ  cacy endpoint.
Four additional studies performed secondary data analysis 
of clinical trials of eszopiclone containing either older adult 
only or mixed-age samples.
In an abstract, McCall and colleagues (2004) conducted 
a pooled analysis of two randomized, double-blind, placebo-
controlled evaluations (Erman and colleagues (2005) and 
Scharf and colleagues (2005)) of adults between 64 and 85 
years old (n’s = 207 and 215). In both studies, the patients 
received nightly treatment with eszopiclone 2 mg or placebo 
for 2 weeks. The pooled analysis found that eszopiclone was 
well tolerated and patients taking eszopiclone experienced 
improvements in sleep maintenance, quality, and next 
day functioning. Patients taking eszopiclone experienced 
improvements in median SL (p   0.0001), WASO (p   0.01), 
TST (p   0.0001), sleep quality (p   0.01), and sleep depth 
(p   0.0007) versus placebo.
In another abstract, Amato and colleagues (2005) con-
ducted Pearson correlation coefﬁ  cients in an analysis of a 
randomized, double-blind, placebo-controlled, parallel-group 
study of 159 people with primary insomnia aged 64–85. 
Table 1 Clinical trials in older adults
Author &   Population   Study design   Treatment   Measurement   Summary 
date       dosages    
Erman et al   N = 264   R,DB,PC;   Eszopiclone   Assessed with PSG:   Eszopiclone 2 mg 
(2004)   (65–85 y)   2 week   2 mg;   LPS, SE, WASO, and #   signiﬁ  cantly decreased 
  primary   duration   placebo   of awakenings; twice   objective LPS (p   0.0001) 
  insomnia       daily with IVRS:   and WASO (p   0.05) and 
        SL,WASO, TST,   subjective SL (p   0.001) 
        quality and depth of   and WASO (p = 0.0019). 
        sleep, and morning   Morning sleepiness was less 
        sleepiness; with ISI and   for the eszopiclone group 
        SF: QoL   than with placebo (p = 
          0.07); There were no 
         signiﬁ  cant differences 
          between groups on other 
         daytime  functioning 
         measures.
Scharf et al   N = 231   R,DB,PC,MC;   Eszopiclone   IVRS: SL,TST,WASO,   Eszopiclone 2 mg group had 
(2005)   (65–85 y)   2 week   1 mg; 2 mg;   number of awakenings,   signiﬁ  cantly shorter SL 
  primary   duration   placebo   daytime functioning,   (p = 0.0034), TST (p = 0.0003), 
  insomnia       Q-LES-Q : QoL   WASO (p   0.05), and sense 
          of physical well-being 
         (p   0.05) compared with 
          placebo; 1 mg signiﬁ  cantly 
          decreased SL (p   0.012) 
          compared with placebo, 
          but was not signiﬁ  cant on 
          any other efﬁ  cacy 
         endpoint. 
Abbreviations: R, randomized; DB, double-blind; PC, placebo-controlled; PSG, polysomnography; IVRS, interactive voice response system; ISI, Insomnia Severity Index; SF, 
SF-36 questionnaires; OL, open-label; MC, multicenter; DSST, Digit Symbol Substitution Test; PG, parallel-group; Q-LES-Q, quality of life enjoyment and satisfaction question-
naire; LPS, latency to persistent sleep; SL, sleep latency; SE, sleep efﬁ  ciency; WASO, wake after sleep onset; TST, total sleep time; QoL, quality of life. Clinical Interventions in Aging 2007:2(3) 317
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Patients either received eszopiclone 2 mg (n = 79) or placebo 
(n = 80). The analysis tested the correlation between daytime 
alertness, ability to function, and physical well-being and 
sleep quality, total sleep time, wake time after sleep onset, 
and sleep latency. This study also examined the percent of 
treatment effect on the next day function variables (daytime 
alertness, ability to function, and physical well-being) attrib-
utable to the effect of eszopiclone on sleep. In both groups, 
the next day function variables correlated highly with sleep 
quality (r ≈ 0.5) and to a lesser extent with TST (r ≈ 0.3), 
WASO, and SL (r ≈ 0.2).
Rosenberg et al (2004) analyzed four studies of eszopi-
clone use in elderly and non-elderly patients with primary 
insomnia to determine if results were similar in both popu-
lations. The studies were randomized, double-blind, and 
placebo-controlled. Two 2-week studies of eszopiclone 
2 mg in elderly patients and two non-elderly studies of 
eszopiclone 3 mg were analyzed. The ﬁ  rst elderly study 
used polysomnography and subjective measures (n = 264; 
Erman, Rosenberg, and Caron, 2004), and the second study 
used subjective measures only (n = 159). One of the non-
elderly studies was a 6-week polysomnographic and subjec-
tive study (n = 204), and the second study was a six month 
subjective study (n = 788; Krystal et al. 2003). In all four 
studies, patient reports of sleep onset (p   0.01), WASO 
(p   0.05), and TST (p   0.01) improved compared with 
placebo. In the objective studies, eszopiclone signiﬁ  cantly 
improved sleep onset, TST, and WASO in both populations 
(p   0.05) compared to placebo. This study is published 
as an abstract.
In an abstract, Gary et al (2004) examined pharmaco-
kinetic and pharmacodynamic effects of eszopiclone. They 
analyzed two studies of healthy adults who were administered 
eszopiclone. In one study, non-elderly adults (n = 48, ages 
18–45) were administered 1, 2, 3, and 5 mg of eszopiclone. 
In the other study, elderly adults (n = 36, ages 65–79) were 
administered 1, 3, and 6 mg. Plasma concentrations were 
measured, and the digit symbol substitution test (DSST), a 
measure of psychomotor performance, attention and abil-
ity to remember and operate on complex symbols) was 
administered. In both studies, eszopiclone was absorbed 
rapidly and plasma levels became steady by approximately 
48 hours. Peak plasma concentration levels were reached at 
1–1.25 hour post-dose. The 2 mg proﬁ  le in older adults was 
consistent with the 3 mg proﬁ  le in non-elderly adults. Based 
on the pharmacokinetic and pharmacodynamic proﬁ  les from 
these studies, 2 mg for older adults and 3 mg for non-elderly 
adults are the targeted doses for treatment.
In a poster presentation, Doghramji and colleagues 
(2006) conducted a mixed-age, open-label, multi-center trial 
of eszopiclone with 2606 individuals. On day 1, ten tablets 
of eszopiclone 1 mg, 2 mg, or 3 mg were administered to 
adults ages 15–91 according to their ages, sleep complaint, 
and medical condition. The mean age of participants was 
50-years-old, 68% were female, 56% presented with second-
ary insomnia, and 44% had primary insomnia. Unfortunately, 
the proportion of the sample that was age 65 and older was 
not reported. Thirty seven percent of participants reported 
suffering from depression, 26% from anxiety, and 11% from 
arthritis. Participants used eszopiclone for up to 10 nights 
over a 10–14 day time span. Participants were given a ques-
tionnaire to ﬁ  ll out rating their satisfaction with eszopiclone 
and its safety and tolerability. Results revealed that 50% of 
the participants preferred eszopiclone to zolpidem (n = 896) 
and trazodone (n = 150).
Trials in non-elderly adults
To date, there have been ﬁ  ve clinical trials (Krystal et al 2003; 
Zammit et al 2004; Rosenberg et al 2005; Roth et al 2005) of 
the safety and efﬁ  cacy of eszopiclone on non-elderly adults. 
Three of the trials examined the effect of eszopiclone on 
chronic insomnia,one study analyzed its effect on transient 
insomnia, and one study examined eszopiclone’s relation-
ship to ﬂ  uoxetine and depression. The methods employed 
by these trials and their key outcomes are described in the 
table below. As with the trials of eszopiclone on older adults, 
much of the data is limited to abstracts, none of the trials 
compared eszopiclone to cognitive-behavioral therapy for 
insomnia, and all clinical trials were funded by Sepracor, 
the manufacturer of eszopiclone. Table 2 provides a concise 
summary of these trials.
Rosenberg and colleagues (2005) studied wake time, 
sleep latency, number of awakenings, and perceptual speed 
in a sample with normal sleep habits. They found that doses 
1–3.5 mg resulted in signiﬁ  cantly reduced wake time, all 
doses (p   0.05) except the 1 mg dose signiﬁ  cantly reduced 
SL (p   0.0001), and the number of nighttime awakenings 
was signiﬁ  cantly reduced (p   0.02) in the 3 and 3.5 mg dose 
groups. The authors found no decrement in morning DSST 
scores for any of the dosage groups.
In a sample diagnosed with chronic primary insomnia, 
Krystal and colleagues (2005) found that a dose of 3 mg 
of eszopiclone signiﬁ  cantly improved SL, TST, NWAK, 
WASO, and quality of sleep (p   0.03) compared to placebo. 
Additionally, daytime ratings of function, alertness, and 
physical well being were higher with eszopiclone. Using the Clinical Interventions in Aging 2007:2(3) 318
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Table 2 Clinical trials in adults
Author &   Population   Study design   Treatment   Measurement   Summary 
date       dosages    
Rosenberg   N = 436 (25–50 y)   MC, R, DB,   Eszopiclone 1,   Assessed with PSG,   Eszopiclone signiﬁ  cantly 
et al   normal sleep   PC, PG;   2, 3, 3.5 mg;   DSST, Self-report:   reduced latency to 
(2005)   habits   ﬁ  rst-night   placebo   SL, SE, number of   persistent sleep (p   0.0001) 
    effect model     awakenings, morning   in all doses except 1 mg. All 
        sleepiness   doses signiﬁ  cantly reduced 
         wake  time  (p   0.05). 
          Number of awakenings was 
          reduced in the 3 and 3.5 mg
         groups  (p   0.02). There 
          were no decrements in next 
          morning DSST scores in 
          any treatment group. 
Krystal N = 788 (21–69 y)   R, DB, PC;   Eszopiclone   Assessed with IVRS:   Eszopiclone improved all 
et al (2003)   Primary,   out-patient,   3 mg; placebo   SL, TST, number of   efﬁ  cacy parameters 
  chronic   monthly     awakenings, WASO,   (p   0.03) versus placebo. 
  insomnia   visits,     quality of sleep, next   Next day function, 
    6-month     day ratings of   alertness, and sense of 
    duration     function, daytime   physical well being were 
        alertness, and sense   better with eszopiclone 
        of physical well being   (p   0.003) in monthly 
         ratings. 
Roth et al   N = 471 (21–64 y)   OL, 6-month   Eszopiclone   continuation of   Patients previously treated 
(2005)   Primary,   extension   3 mg   parameters in   with placebo reported 
  chronic   phase (for     Krystal et al   signiﬁ  cant and rapid 
  insomnia.   combined       improvements in sleep and 
  (Continuation of   total of 12       day time functioning 
  Krystal et al   months)       (p   0.0001). 
 study)         
Zammit   N = 308   R, DB, PC,   Eszopiclone 2,   PSG (nights 1, 15, 29)   SL, TST, SE, and WASO 
et al (2004)   M age = 39.8 y;   PG; 44   3 mg; placebo   and patient-reports   signiﬁ  cantly improved with 
  range 21–64 y);   consecutive     (nights 1, 15, 29   eszopiclone 3 mg versus 
  Chronic   nights with 2     43–44); DSST: next-day   placebo (all ps    0.05). 
  primary   nights of     effects   Eszopiclone 2 mg improved 
  insomnia   single-blind       all of those parameters 
    placebo       except WASO. There were 
          no decrements in next 
          morning DSST scores in 
          any treatment group. 
Fava et al   N = 545 M age =   R,DB,PC,PG,   Fluoxetine   HAM-D-17; and   Decreased SL (p   0.001) and 
(2006)   40.4 y; range   OL; 8 weeks   hydrocholoride,   IVRS (3–7 days for   WASO (p   0.002) and 
  21–64; Major   then all   20–40 mg; with   baseline); ISI; CGI-S   increase in TST (p   0.0004), 
  Depressive   patients   Eszopiclone     SQ (p   0.0002) , DS 
  Disorder and   received SB   3 mg; or     (p   0.0007) in the eszopiclone 
  insomnia   placebo for 2   placebo     and ﬂ  uoxetine group 
    additional       compared to placebo. 
    weeks       Scores also signiﬁ  cantly 
          improved on the HAM-D-17
          (week 4, p   0.01, week 8, 
         p    0.002) in the co-therapy 
         group. 
Abbreviations: R, randomized; DB, double-blind; SB, single blind; PC, placebo-controlled; PSG, polysomnography; IVRS, interactive voice response system; ISI, Insomnia 
Severity Index; SF, SF-36, questionnaires; OL, open-label; MC, multi-center; DSST, Digit Symbol Substitution Test; PG, parallel-group; Q-LES-Q, quality of life enjoyment and 
satisfaction questionnaire; CGI-S, Clinical Global Impression severity; HAM-D-17, Hamilton Depression Scale; LPS, latency to persistent sleep; SL, sleep latency; SE, sleep 
efﬁ  ciency;  WASO, wake after sleep onset; TST, total sleep time; SQ, sleep quality; DS, Depth of Sleep; QoL, quality of life. Clinical Interventions in Aging 2007:2(3) 319
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same sample, Roth and colleagues (2005) found that partici-
pants who were previously treated with placebo showed rapid 
improvements in sleep and daytime functioning measures 
(p   0.003) when treated with the 3 mg eszopiclone dose.
In a sample of adults with chronic insomnia, Zammit 
and colleagues (2004) found that all sleep parameters (SL, 
TST, WASO, and SE) improved under the 3 mg dose condi-
tion, while all parameters except for wake time after sleep 
onset improved in the 2 mg dose condition. There were no 
impairments in the DSST observed in any of the treatment 
groups.
The Fava et al (2006) study examined the effects of 
eszopiclone and ﬂ  uoxetine co-administered to individu-
als 21–64 years. All participants met DSM-IV criteria for 
Major Depressive Disorder and insomnia. All participants 
began receiving 20 mg ﬂ  uoxetine daily for 8 weeks. At 
week 4, there was the option for an increase from 20 mg to 
40 mg depending on depressive symptoms at that time. The 
545 participants were randomized into 3 mg eszopiclone 
or placebo groups at week 4. The majority of participants 
(n = 373; 68.4%) completed the trial. An interactive voice 
response system was used daily during baseline and the day 
of and day after scheduled clinic visits through week 6 and 
daily from weeks 8 through 10. Participants also completed 
the insomnia severity index (ISI) and Hamilton depression 
scale (HAM-D-17) at weeks 0, 4, 8, and 10. They completed 
the Clinical Global Impression Scale (CGI) at every ofﬁ  ce 
visit. An 11-point Likert scale was also used to examine 
wake time after sleep onset, SL, sleep quality, sleep depth, 
daytime alertness and ability to function, sense of physical 
well-being, and ability to concentrate. Participants in the 
eszopiclone and ﬂ  uoxetine group reported improvements in 
SL (p   0.001), WASO (p   0.002), and TST (p   0.0004). 
Participants in this group also reported improvements in 
depth of sleep (p   0.0007) and sleep quality (p   0.0002). 
The co-therapy group did not report a signiﬁ  cant change in 
sense of well-being (p = 0.1); although they did report an 
increase in daytime alertness (p = 0.03), ability to function 
(p = 0.007), and ability to think clearly and concentrate 
(p = 0.02). Participants in this group also had signiﬁ  cantly 
reduced HAM-D-17 scores at Week 4 (p = 0.01) and Week 8 
(p = 0.002). The participants in the eszopiclone and ﬂ  uoxetine 
group that were more severely depressed at baseline experi-
enced the most signiﬁ  cant changes in depressive symptoms 
at Week 4 (p = 0.005) and Week 8 (p = 0.0007).
In an additional study described in the Formulary of 
the annual North American Menopause Society meeting 
for 2006, a trial of eszopiclone and menopausal-associated 
insomnia was conducted with a group of women aged 40 
to 60 years. Four hundred and ten peri-menopausal and 
menopausal women participated and were randomized into a 
3 mg eszopiclone or placebo group. At the 4-week follow-up, 
women who received eszopiclone reported signiﬁ  cant reduc-
tions in SL and WASO compared to those taking placebo. 
The median reduction of SL for the eszopiclone group was 
18.6 minutes compared to the 8.1 minute reduction in the 
placebo group. The median reduction in WASO was 30.6 
minutes versus 1.6 minutes in the placebo group. The fre-
quency or duration of hot ﬂ  ashes was not affected. The names 
of the investigators were not provided.
Four additional studies conducted secondary data analy-
ses of the clinical trials of eszopiclone in adults.
Krystal et al (2004) analyzed the Krystal et al (2003) study. 
Participants were grouped into a low (   30 min; n = 190) 
and high ( 30 min; n = 319) WASO. This analysis found that 
signiﬁ  cant differences were noted in both the low (p = 0.0035) 
and high (p = 0.030055) WASO. The amount of WASO reduc-
tion was directly related (p   0.001) to baseline wake time 
after sleep onset impairment. If the Krystal et al (2003) trial 
had used the WASO >30 minute criteria, which is standard 
for insomnia research, then approximately 40% of participants 
would have been excluded from the original study.
Buysse and colleagues (2004) performed a trajectory 
analysis of the Krystal et al (2003) trial. They analyzed the 
data using a SAS Traj procedure which calculated the prob-
ability of subjects belonging to a trajectory and assigned 
each subject to a particular trajectory. Buysse and colleagues 
(2004) tested linear and quadratic mixture models using 
separate models for the eszopiclone and placebo groups. The 
eszopiclone subgroups showed rapid treatment response and 
a stable course or slight improvement over the 6-month study 
period. The placebo subgroup showed a stable course or slight 
improvement during the study period. The results of these 
analyses were consistent with other results in that eszopiclone 
was associated with rapid and sustained response.
McCall and colleagues (2006) also analyzed the Fava 
et al (2006) trial. They analyzed the trial study to determine 
whether baseline sleep severity inﬂ  uenced response to the 
eszopiclone/ﬂ  uoxetine co-therapy. Participants were stratiﬁ  ed 
by baseline insomnia severity (moderate = ISI score  18; 
severe = ISI score  18). Results found that eszopiclone/
ﬂ  uoxetine co-therapy resulted in signiﬁ  cant improvements in 
sleep and depression measure in participants with moderate 
and severe insomnia compared to monotherapy.
Krystal and colleagues (2006) analyzed the individual 
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(2006) study (see the Drug Interactions section for more 
information) examining eszopiclone and ﬂ  uoxetine. All tests 
were two-sided and were conducted at a 5% signiﬁ  cance 
level. The continuous variables were compared using an 
analysis of covariance model across treatment groups. This 
analysis found that eszopiclone/ﬂ  uoxetine co-therapy sig-
niﬁ  cantly improved the insomnia items on the HAM-D17. 
Also, several of the co-depressive symptoms improved with 
co-therapy as opposed to monotherapy.
See below for information regarding studies examining 
eszopiclone, drug interactions and adverse effects.
Clinical considerations
Adverse events
After reviewing the literature, the most common adverse 
effects of eszopiclone are unpleasant taste, headache, som-
nolence, dizziness and dry mouth. Different adverse effects 
for the non-elderly and elderly have been reported as shown 
in Tables 3 and 4. The product packaging information for 
eszopiclone is the only source which provides the frequency 
of adverse effects. These frequency levels reveal the most 
extensive consequences of eszopiclone and were repro-
duced in table form and supplemented by other published 
information.
Drug interactions
After reviewing the current literature for drug interactions, no 
speciﬁ  c contraindications to eszopiclone use could be found 
(see Table 5). Eszopiclone, like its predecessors – zolpidem, 
zaleplon, and the benzodiazepines – does not, when working 
by itself, create a dangerous degree of central nervous system 
(CNS) depression. However, eszopiclone can be deadly if 
taken with large doses of other CNS depressants (including 
alcohol) and may have an addictive effect (Anon 2005b). It is 
warned that Potent CYP3A4 inhibitors such as ketoconazole, 
itraconazole (Sporanox), clarithromycin (Biaxin) and ritona-
vir (Norvir) could increase serum concentrations of eszopi-
clone and prolong its duration of action (Anon 2005c). So if 
a potent CYP3A4 is taken concurrently with eszopiclone, the 
dose of the latter should be reduced. Caution should also be 
taken when giving eszopiclone to those with compromised 
respiratory function. However, 7 mg given to healthy volun-
teers did not cause respiratory-depressant effects (Sepracor 
2005). As with all sleeping medications, causes of insomnia, 
including physical or psychiatric, should be assessed before 
a drug treatment is started. This assessment should include 
a thorough history focusing on severity, functional impact, 
and persistence of complaints. Precautions should be taken 
when using sleep medications, such as eszopiclone, in the 
following populations: elderly; debilitated; and those with 
depression, and concomitant drug therapy; current illnesses, 
speciﬁ  cally diseases that could affect the liver, metabolism, 
or hemodynamic responses (Sepracor 2005). Caution should 
be taken when prescribing eszopiclone to those with depres-
sion as suicidal tendencies could be present and intentional 
overdose may occur. An overdose of 36 mg of eszopiclone 
did occur in preclinical trials and proved to be nonfatal 
(Sepracor 2005).
The manufacturers suggest that the starting dose of 
eszopiclone for older adults should be 1 mg not 2 mg 
(Sepracor 2005). Polypharmacy is a concern when prescrib-
ing eszopiclone, because the number of medications being 
taken by older adults has been and will likely continue to 
increase (Vener et al 1979; Stewart et al 1991; Kaufman 
et al 2002; Lernfelt et al 2003). The most common medica-
tions used by older individuals are cardiovascular drugs, 
analgesics, and drugs for diseases in the central nervous 
system (Lernfelt et al 2003). Women age 65 and older have 
the highest prevalence of medication use with 94% taking 
at least 1 medication; 57% taking at least 5 or more; and 
12% taking 10 or more. Rates were similarly high for men 
with 91% taking at least 1 mediation; 44% taking at least 5; 
and 12% taking 10 or more (Kaufman et al 2002). Aspirin 
taken as a cardiovascular prophylaxis was the most com-
monly used medication (58%-M; 51%-W). The following 
drugs which have been tested for interactions, see Table 5, 
were found to be used by older adults: paroxetine (  1%-
both), digoxin (9%-M, 5%-W), warfarin (8%-M, 4%-W), 
and ﬂ  uoxetine (   1%-M, 1%-W) ( Kaufman et al 2002). 
Unfortunately, none of these studies included older adults. 
In the previously described Scharf and colleagues (2005) 
study, 92% of the older adults receiving the 1 mg dose 
of eszopiclone and 89% receiving the 2 g dose were on a 
concomitant medication. The 5 most frequently reported 
medications in that study were aspirin, estrogen, calcium, 
levothyroxine, and acetaminophen (Scharf et al 2005). 
Because polypharmacy is common in older adults, close 
attention to potential drug interactions, particularly for 
other commonly used drugs, may help to prevent adverse 
events such as accidents, falls, nursing home placements, 
and even death.
Tolerance/dependence
Use of a sleep medication nightly for greater than a few 
weeks may cause the medication to lose its effectiveness in 
engendering sleep, this is called tolerance (tachyphylaxis). Clinical Interventions in Aging 2007:2(3) 321
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Table 3 Adverse effects reported by non-elderly adult patients
  Frequent AE’s   Infrequent AE’s   Rare AE’s 
  at least 1 in 1/100   between 1/100 & 1/ 1,000   fewer than 1/1,000 
Body as a whole   Headache, chest pain,   Allergic reaction, cellulitis,  
  viral infection,   face edema, fever, halitosis,  
  abdominal pain,   heat stroke, hernia, malaise,  
  abnormal dreams,   neck rigidity, photosensitivity,  
  asthenia, accidental   diabetes mellitus,  
  injury, pain    
Cardiovascular system   Migraine   Hypertension   Thrombophlebitis. 
Digestive System   Dry mouth, dyspepsia,   Anorexia, cholelithiasis,   Colitis, dysphagia, gastritis, 
  nausea, vomiting,   increased appetite, melena,   hepatitis, hepatomegaly, 
  diarrhea, pharyngitis   mouth ulceration, thirst,   liver damage, stomach 
    ulcerative stomatitis   ulcer, stomatitis, tongue 
      edema, rectal hemorrhage 
Hemic and Lymphatic     Anemia, lymphadenopathy  
System      
Metabolic and   Peripheral edema   Hypercholesteremia, weight   Dehydration, gout, 
Nutritional     gain, weight loss   hyperlipemia, hypokalemia 
Musculoskeletal System   Back pain   Arthritis, bursitis, joint   Arthrosis, myopathy, ptosis 
    disorder (mainly swelling,  
    stiffness, and pain), leg  
    cramps, myasthenia,  
   twitching,   
Nervous System   Anxiety, confusion,   Agitation, apathy, ataxia,   Abnormal gait, euphoria, 
  depression, dizziness,   emotional lability, hostility,   hyperesthesia, 
  hallucinations, libido   hypertonia, hypesthesia,   hypokinesia, neuritis, 
  decreased,   incoordination, insomnia,   neuropathy, stupor, 
  nervousness,   memory impairment,   tremor 
  somnolence   neurosis, nystagmus,  
   paresthesia,  reﬂ  exes  
    decreased, thinking  
    abnormal (mainly difﬁ  culty  
    concentrating), vertigo  
Respiratory System   Infection, rhinitis,   Asthma, bronchitis, dyspnea,  
  sinusitis   epistaxis, hiccup, laryngitis  
Skin and Appendages   Rash,   Acne, alopecia, contact   Erythema multiforme, 
    dermatitis, dry skin, eczema,   furunculosis, herpes zoster, 
    skin discoloration, sweating,   hirsutism, maculopapular 
    urticaria   rash, vesiculobullous rash 
Special Senses   Unpleasant taste   Conjunctivitis, dry eyes, ear   Hyperacusis, iritis, 
    pain, otitis externa, otitis   mydriasis, photophobia 
    media, tinnitus, vestibular  
   disorder   
Urogenital System   Dysmenorrhea   Amenorrhea, breast   Oliguria, pyelonephritis, 
  (women)   engorgement, breast   urethritis 
  (women)   engorgement, breast    
    enlargement, breast  
  gynecomastia (men)  neoplasm, breast pain,  
    cystitis, dysuria, female  
    lactation, hematuria, kidney  
    calculus, kidney pain,  
    mastitis, menorrhagia,  
    metrorrhagia, urinary  
    frequency, urinary  
    incontinence, uterine,  
    hemorrhage, vaginal  
    hemorrhage, vaginitis  
Adapted from (Krystal et al 2003; Zammit et al 2004; Melton et al 2005; Rosenberg et al 2005; Roth et al 2005; Sepracor 2005). Doses range from 1 to 3.5. Other symp-
toms for which frequency information could not be obtained include: ﬂ  u syndrome, myalgia, and a non fatal overdose.Clinical Interventions in Aging 2007:2(3) 322
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There have been studies testing the sustained beneﬁ  t of 
3 mg of eszopiclone for a 6 week (Zammit et al 2004), 6 
month (Krystal et al 2003), and 12 month period (Roth et al 
2005). None of these studies showed evidence of pharmaco-
logic tolerance. However, further research is needed to test 
eszopiclone’s discontinuation effects (Roth et al 2005). The 
worsening of sleep relative to baseline values after discon-
tinuation of the medication is known as rebound insomnia 
(Gillin et al 1989). Rebound insomnia has been associated 
with use of benzodiazepines (Hegelbach-Feller et al 1988). 
Eszopiclone, which shares some pharmacologic properties 
of benzodiazepines, is under the same classiﬁ  cation, sched-
ule IV controlled substance, as benzodiazepines (Sepracor 
2005). Most controlled studies with eszopiclone found it 
was not signiﬁ  cantly associated with rebound insomnia 
(Krystal et al 2003, 2005; Zammit et al 2004; Erman et al 
2005; Fava et al 2006). However, this was not exclusively 
the case (Anon 2005c). One study found rebound insomnia 
on the ﬁ  rst night in patients discontinuing the 2 mg dose of 
eszopiclone, and patients discontinuing the 3 mg dose had 
diminished sleep efﬁ  ciency (time asleep/8 hours) on the ﬁ  rst 
night (Anon 2005c). In addition to tolerance and rebound 
insomnia, withdrawal following discontinuation is another 
major concern associated with hypnotic medications. No 
serious withdrawal effects were seen with eszopiclone. The 
following adverse events from the DSM-IV criteria for un-
complicated sedative/hypnotic withdrawal were, however, 
seen within 48 hours after discontinuing eszopiclone usage: 
anxiety, abnormal dreams, nausea, upset stomach, hyperes-
thesia, and neurosis (Sepracor 2005). There were no reports 
of seizures, hallucinations, or perceptual-disturbance; events 
that are commonly reported withdrawal symptoms following 
discontinuation of sedative/hypnotic medications (Sepracor 
2005). Nonetheless, the manufacturer urges caution when 
prescribing eszopiclone for patients with history of alcohol 
or substance abuse and dependence.
The use of benzodiazepines and similar medications, like 
eszopiclone, could lead to both physical and psychological 
dependence. This increases with not only the dose and dura-
tion of the treatment but also use of other mediations, and 
in patients with a history of alcohol/drug abuse or history of 
psychiatric disorders. The term, hypnotic dependent insomnia, 
is used to describe a special type of dependence characterized 
by insomnia or excessive sleepiness associated with toler-
ance to or withdrawal from hypnotic medications. The use 
of benzodiazepine as hypnotics has been occurring since the 
1960s and before that the barbiturates were used as hypnot-
ics. Nonetheless a variety of abnormal thinking and behavior 
changes have been shown to transpire with the use of sedative/
hypnotics (Sepracor 2005). Characteristics of these changes 
are decreased inhibitions (out of character extraversion and 
aggression); bizarre behavior agitation; hallucinations; dep-
ersonalization; sporadic amnesia and other neuropsychiatric 
symptoms; and in those with depression, worsening of the 
disorder including suicidal ideology (Sepracor 2005). Discon-
tinuation or rapid decrease of such mediations produces effects 
analogous to alcohol and other CNS depressants. To establish 
the abuse liability of eszopiclone, individuals known to abuse 
benzodiazepines were given eszopiclone at twice the recom-
mended dose, 6 and 12 mg. This resulted in euphoric effects 
Table 4 Adverse effects reported by elderly adults1
  Frequent AE’s   Other AE’s 2
  at least 1 in 1/100   reported AE’s with missing frequency 
Body as a whole   Accidental injury,   Asthenia, impaired psychomotor 
  headache, pain   functioning (9.5 hrs. post drug, 
    compared to placebo), moderate atypical chest pain3 
Digestive System   Dry mouth, dyspepsia,   Abdominal pain, nausea 
 diarrhea,   
Nervous System   Abnormal dreams,   Somnolence, next day memory 
  dizziness, neuralgia,   impairment 
 nervousness,   
Skin and Appendages   Pruritis   Rash 
Special Senses   Unpleasant taste  
Urogenital System   Urinary tract Infection  
1More information on this population is required to gain a fuller view of AE’s although, the labeling text does report the overall pattern of AE’s for elderly subjects was not 
different from younger adults.
2Due to sample size of many studies full frequency information is unavailable.
3Reported but deemed unrelated to treatment.Clinical Interventions in Aging 2007:2(3) 323
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(at both doses) similar to those of diazepam 20 mg as well as 
amnesia and hallucinations (Sepracor 2005). In older adults, 
hypnotics may not be associated with an increased mortality 
risk, but this population may be more sensitive and are more 
likely to experience adverse effects (McCall 2005). This is 
particularly true with long durations of use and high dosages. 
Other restrictions on the use of hypnotics in older adults 
consist of potential risk of accidents (ie, falls, motor vehicle 
accidents cause by slowed reactions), anterograde amnesia, 
and diminished effectiveness over time. The manufacturer 
suggests careful monitoring for tolerance or dependence in 
patients on long-term drug therapy.
Economics/cost
Table 6 compares the cost of various dosages of eszopiclone 
to 2 other popular and relatively new nonbenzodiazepine 
hypnotic agents – zaleplon and zolpidem (benzodiazepine 
receptor agonists) and to the newly introduced melatonin 
receptor agonist hypnotic agent – ramelteon. Although 
more expensive than older hypnotic agents, eszopiclone is 
Table 5 Drug interactions with eszopiclone
Drug   Effect 
Ethanol   Coadministration of eszopiclone and ethanol 0.70 g/kg, showed an additive effect on psychomotor 
  performance up to four hours after ethanol administration. 
Ketoconazole   Concomitant administration of eszopiclone 3 mg and ketoconazole 400 mg, which is a potent 
  inhibitor of P450 CYP3A4. The total amount of eszopiclone absorbed by the body increased by 
  2.2 when given ketoconazole for 5 days. The time to peak effectiveness increased by 1.4 and half 
  life increased by 1.3. Other inhibitors of CYP3A4: itraconazole, clarithromycin, nefazodone, 
 ritonavir,  nel-ﬁ  navir, are expected to act the same way although they have not been tested and no 
 speciﬁ  c recommendations for dose adjustments are made in the prescribing information. 
Paroxetine   Coadministration of eszopiclone 3 mg and paroxetine 20 mg for 7 days had no clinically 
 signiﬁ  cant pharmacokinetic or pharmacodynamic interact there was a small increase in peak 
  effectiveness of paroxetine 1.5% and eszopiclone 12%. 
Digoxin   A single dose of eszopiclone 3 mg did not affect the steady state pharmacokinetics of digoxin in 
  healthy volunteers, there was no recommendation of dose adjustment. 
Warfarin   Coadminstration of eszopiclone 3 mg and a single warfarin 25 mg oral dose, daily for 5 days did 
  not affect the pharmacokinetics nor the anticoagulant effect of the warfarin. 
Lorazepam   Coadministration of eszopiclone 3 mg with lorazepam 2 mg decreased eszopiclone’s peak 
  concentration by 22.69% and lorazepan’s by 21.1%, this was not considered a clinically relevant 
 difference. 
CNS depressant   Caution should used when giving patients a combination of Eszopiclone and CNS drugs (ie, 
drugs   anticonvulsants, antihistamines and psychotropic medication). This combination may cause 
  addictive CNS depression. 
Olanzapine   Coadministration of single doses of eszopiclone 3 mg and olanzapine 10 mg formed a 
  pharmacodynamic interaction and produced a decrease in a measure of psychomotor function. 
  The pharmacokinetics of both drugs were unaltered. The manufacturer makes no speciﬁ  c 
  recommendation for dose adjustments of either drug. 
Fluoxetine   Among patients with insomnia and co-existing major depressive disorder co-administration of 
  eszopiclone 3 mg in combination with ﬂ  uoxetine QAM well tolerated and did not seem to 
  undermine the antidepressant response of ﬂ  uoxetine. 
Effect of food   Coadministration of eszopiclone 3-mg after a high-fat meal resulted in no change in total amount 
  of drug absorbed by the body, a reduction in peak concentration of 21% and a 1-hour delayed 
  time to reach peak concentration. Manufacturer warns that eszopiclone’s effects maybe reduced 
  if it is taken with or immediate after a high-fat/heavy meal. 
Rifampin   Rifampicin signiﬁ  cantly decreased exposure to racemic zopiclone by 80% and a similar effect 
  would be expected with eszopiclone. In subjects aged ≥65 years, the total amount of drug 
  absorbed by the body increased by 41% and prolonged elimination of eszopiclone (t1/2 ~9 h) 
  when compared to non-elderly adults, but peak concentration was unchanged. The 
  manufacturer recommends no dose adjustments when the two drugs are coadministered. The 
  starting dose of eszopiclone in geriatric patients should be 1 mg, with a recommended maximum 
  dose of 2 mg. Clinical Interventions in Aging 2007:2(3) 324
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similar in cost to the newer nonbenzodiazepine hypnotics 
and less expensive than ramelteon. The cost of 2 weeks of 
eszopiclone treatment for transient insomnia is approxi-
mately US$46.62–US$49.28. The cost for treating chronic 
late-life insomnia is considerably higher. In two recent 
community-based surveys of older adults’ sleep patterns, 
individuals with insomnia reported experiencing difﬁ  culties 
for 7–12 years on average (McCrae et al 2003, 2005). Once 
daily treatment (one tablet per day) for 7 years would cost 
approximately US$8,500–US$9,000 and for 12 years would 
cost US$14,600–US$15,400.
Compared to nonpharmocological treatments, such as 
cognitive behavioral therapy for insomnia, long-term use 
of eszopiclone is more expensive. For example, the average 
duration of cognitive-behavioral therapy for insomnia is 
6–10 sessions. Typically, each session lasts 50 minutes. At 
a cost of $150/session, the total cost of cognitive-behavioral 
therapy ranges from $900–$1500, making it considerably 
cheaper than on-going treatment with eszopiclone. Speciﬁ  -
cally, cognitive-behavioral therapy becomes more affordable 
after 9–15 months of daily eszopiclone treatment. Addition-
ally, as described below, clinical trial evidence supports 
cognitive-behavioral therapy’s effectiveness for insomnia 
in older adults.
Other treatment considerations 
for older adults
Because older adults frequently suffer from chronic insom-
nia, effective treatment needs to provide not only short-term 
improvement, but also long-term maintenance (6 months or 
more). Despite the fact that eszopiclone’s length of use is not 
restricted, the available evidence does not address whether it 
provides the long-term maintenance that many older adults 
require. Each of the 3 clinical trials that focused on older 
adults were only 2 weeks in duration. Although other clini-
cal studies have shown that eszopiclone can be used over 
periods of 6 and 12 months without evidence of problems, 
the maximum age of participants in those trials was 69. No 
long-term studies have been conducted in the old-old (75–84) 
or oldest-old (85+) age groups.
The role of learning (development of sleep preventing 
behaviors and associations) in the maintenance of chronic 
insomnia is another reason for caution in the use of eszopi-
clone or any other hypnotic medication for treating older 
adults. Insomnia is precipitated by a wide variety of factors, 
including medical and psychiatric illnesses. Over time, 
insomnia that begins due to one of these factors often leads 
to sleep preventing behaviors (ie, spending too much time 
in bed, trying too hard to sleep, increasing caffeine), asso-
ciations (ie, associating the bed and bedroom with anxiety 
over inability to sleep, becoming fearful over awakening 
during the night), and physiological arousal. Over time, 
these behaviors and associations often serve to perpetuate 
the insomnia. Because older adults are likely to experience 
1 or more chronic conditions, they are particularly vulner-
able to developing these sleep-preventing behaviors and 
associations. Thus, cognitive-behavioral therapy for in-
somnia, which is designed to reverse both sleep-preventing 
associations and behaviors as well as reduce psychophysi-
ological arousal, should always be considered as either an 
alternative or an adjunct to hypnotic therapy. Many patients 
rate cognitive-behavioral techniques for insomnia as more 
Table 6 30 Day and per pill cost comparisons (in US dollars) for eszopiclone, ramelteon, zaleplon, zolpidem, and zolpidem-cr
Generic name  Brand name (manufacturer)  Dosages   Cost for 30 day supply   Per pill cost5
Eszopiclone  Lunesta  1, 2, & 3 mg   $105.67/$99.951,2   $3.52/$3.33
 (Sepracor)     
Ramelteon Rozerem  8 mg $139.95/$149.003,4 $4.67/$4.97
 (Takeda  Pharmaceuticals)     
Zaleplon   Sonata  5 mg $89.99/$67.951,2 $3.00/$2.27
 (King)  10 mg   $95.81/$89.951,2 $3.19/$3.00
Zolpidem Ambien  5 mg $104.99/$72.951,2 $3.50/$2.43
 (Sanoﬁ  -Aventis)  10 mg   $104.99/$93.951,2 $3.50/$3.13
Zolpidem-  Ambien CR (Sanoﬁ  -Aventis)  6.25, 12.5 mg   $102.99/$88.881,2 $3.43/$2.96
Extended Release       
1Retail cost information based on US dollars for a 30 day supply (1 pill per day) purchased from drugstore.com (August 8, 2006).
2Retail cost information based on US dollars for a 30 day supply (1 pill per day) purchased from drugstoreScripts.com (August 8, 2006).
3Retail cost information based on US dollars for a 30 day supply (1 pill per day) purchased from pharmacies4us.com (August 8, 2006).
4Retail cost information based on US dollars for a 30 day supply (1 pill per day) purchased from usainternetpharmacy.com (August 8, 2006).
5Cost per pill determined by dividing 30 day supply costs by 30 days.Clinical Interventions in Aging 2007:2(3) 325
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acceptable than sleep medications, and approximately 
70%–80% of individuals treated behaviorally show sleep 
improvements (Morin et al 1999). Speciﬁ  cally, the typical 
primary insomnia patient reports decreases in sleep onset 
latency and wake time after sleep onset below or near the 
30-minute criteria commonly used to diagnose insomnia 
(Morin et al 1999).
Although no clinical trials have compared eszopiclone 
to cognitive-behavioral therapy for insomnia, growing 
evidence supports the greater effectiveness of behavioral 
approaches to pharmacological ones for the treatment of 
late-life insomnia. In their recent review, Irwin et al (2006) 
emphasized behavioral therapy over pharmacological 
intervention for older adults (aged 55+). This review of 
23 RCTs (>500 participants) found behavioral treatments 
(cognitive-behavioral treatment for insomnia, relaxation, 
behavioral only treatment for insomnia) produced improve-
ments in sleep quality, sleep onset latency, and awaken-
ings during the night. Effect sizes ranged from medium to 
large (0.38–0.73, ps   0.01) and were comparable to those 
achieved with sleep medications. Importantly, for frequent 
nighttime awakenings which are one of the most common 
complaints of older adults, there was a better than average 
response with behavioral treatment compared to medications. 
Previous research comparing behavioral intervention to sleep 
medications has demonstrated comparable, yet more immedi-
ate effects (meaning sleep improvements are often seen the 
night the medication is taken compared to a potential delay 
of several days to several weeks for behavioral interventions, 
which require time for the patient to adopt new habits and 
behaviors) for pharmacological intervention (McClusky 
et al 1991), but better maintenance of improvements at 9 
week followup for behavioral intervention. Morin and col-
leagues (1999) compared 8 weeks of behavioral treatment to 
temazepam (Restoril; initial dosage 7.5 mg increased up to 
30 mg per night depending on treatment response and adverse 
effects) in older insomniacs. Behavioral intervention alone 
was more effective in sustaining sleep improvements over 
time (up to 24 months) than either medication alone or the 
two treatments combined.
Conclusion
Eszopiclone has been shown to be safe and efﬁ  cacious for 
short-term treatment (2 weeks) of chronic, primary insomnia 
in older adults (64–91 years). Whether eszopiclone is safe 
and effective for older adults when used over longer periods 
has not been examined. This is unfortunate, because older 
individuals frequently suffer from chronic insomnia. For this 
reason, cognitive-behavioral therapy for insomnia, which 
targets the behavioral factors that can maintain chronic 
insomnia, represents an attractive treatment alternative or 
adjuvant to eszopiclone for older adults. To date, no studies 
have compared eszopiclone to other hypnotic medications 
or to nonpharmacological interventions, such as cognitive-
behavioral therapy for insomnia, in older adults. All of the 
clinical trials reported herein were funded by Sepracor, the 
manufacturer of eszopiclone.
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